Larimar Therapeutics
dose dependent increases in levels observed in skin and buccal cells in phase | Larimar Therapeutics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
10 of 44
Similar slides by Larimar Therapeutics
See diffirences between slides (animation)
Investor Presentation
November 2023
increases in levels observed in buccal cells cohort | Larimar Therapeutics
Investor Presentation
November 2023
increases in levels observed in skin cells cohort | Larimar Therapeutics
Investor Presentation
November 2023
dose dependent increases in levels observed in skin and buccal cells in phase | Larimar Therapeutics
Investor Presentation
November 2023
increases in levels in phase trial cohort | Larimar Therapeutics
Related slides by other companies
BioAtla
Investor Presentation
August 2023
change from in sum of target lesions | BioAtla
MindMed
Investor Presentation
December 2024
phase gad part a trials primary key secondary | MindMed
Telia Company
Results
October 2020
group highlights | Telia Company
PaxMedica
Investor Presentation
October 2022
secondary clinical global impression of improvement in overall severity of symptoms change from | PaxMedica
Other recent decks by Larimar Therapeutics
See all presentations (3 decks)
Results
November 2022
Investor Presentation
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights